
Please try another search
ImmuPharma plc, a biopharmaceutical company, discovers and develops peptide-based therapeutics in the United Kingdom. Its peptide-based therapeutics focuses on autoimmunity and inflammation, and anti-infectives therapeutic areas. The company’s lead product candidate includes P140, a peptide technology platform, which is in Phase III clinical trial that targets autoimmune diseases for systemic lupus erythematosus; P140, which is in Phase II clinical trial for the treatment of chronic inflammatory demyelinating polyneuropathy, a rare acquired autoimmune disorder of peripheral nerve; and P140 that covers other indications acute and chronic asthma, gout, irritable bowel disease, and periodontitis. Its pre-clinical products include BioAMB, a peptide-based drug of Amphotericin-B formulations for the treatment of serious and life-threatening fungal infections, such as aspergillosis; and BioCin, a vancomycin based treatment for anti-infection. It has a collaboration arrangement with Centre National de la Recherche Scientifique for the development of 1P40 platform; and license and development agreement with Avion Pharmaceuticals LLC. ImmuPharma plc was founded in 1999 and is headquartered in London, the United Kingdom.
Name | Age | Since | Title |
---|---|---|---|
Laurence Reilly | 43 | 2023 | Senior Non-Executive Director |
Timothy Paul McCarthy | 69 | 2015 | Chairman & CEO |
Timothy Gary Franklin | 61 | 2020 | COO & Director |
Lisa Baderoon | 59 | 2012 | Head of Investor Relations & Independent Non Executive Director |
Vibeke S. Strand | - | 2013 | Member of Scientific Advisory Board |
David A. Isenberg | - | 2013 | Member of Scientific Advisory Board |
Cees GM Kallenberg | - | 2013 | Member of Scientific Advisory Board |
Lee S. Simon | 74 | 2013 | Member of Scientific Advisory Board |
Daniel J. Wallace | - | 2013 | Member of Scientific Advisory Board |
Sebastien R. Goudreau | 44 | 2022 | Independent Non-Executive Director |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review